Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin.

MLA

Jianing Xu, et al. “Mechanistically Distinct Cancer-Associated MTOR Activation Clusters Predict Sensitivity to Rapamycin.” Journal of Clinical Investigation, vol. 126, no. 9, Sept. 2016, pp. 3526–40. EBSCOhost, https://doi.org/10.1172/JCI86120.

APA

Jianing Xu, Pham, C. G., Albanese, S. K., Yiyu Dong, Toshinao Oyama, Chung-Han Lee, Rodrik-Outmezguine, V., Zhan Yao, Song Han, Chen, D., Parton, D. L., Chodera, J. D., Rosen, N., Cheng, E. H., Hsieh, J. J., Xu, J., Dong, Y., Oyama, T., Lee, C.-H., & Yao, Z. (2016). Mechanistically distinct cancer-associated mTOR activation clusters predict sensitivity to rapamycin. Journal of Clinical Investigation, 126(9), 3526–3540. https://doi.org/10.1172/JCI86120

Chicago

Jianing Xu, Can G. Pham, Steven K. Albanese, Yiyu Dong, Toshinao Oyama, Chung-Han Lee, Vanessa Rodrik-Outmezguine, et al. 2016. “Mechanistically Distinct Cancer-Associated MTOR Activation Clusters Predict Sensitivity to Rapamycin.” Journal of Clinical Investigation 126 (9): 3526–40. doi:10.1172/JCI86120.